Neumora Therapeutics, Inc.
NMRA
$1.28
-$0.12-8.57%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 37.52% | 37.00% | 63.66% | 53.16% | 46.12% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 40.00% | 48.47% | 61.95% | 58.65% | 53.17% |
| Operating Income | -40.00% | -48.47% | -61.95% | -58.65% | -53.17% |
| Income Before Tax | -3.37% | -88.78% | -107.95% | -105.49% | -80.02% |
| Income Tax Expenses | -33.58% | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.33% | -89.07% | -108.25% | -105.71% | -80.23% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.33% | -89.07% | -108.25% | -105.71% | -80.23% |
| EBIT | -40.00% | -48.47% | -61.95% | -58.65% | -53.17% |
| EBITDA | -40.16% | -48.67% | -62.20% | -58.87% | -53.36% |
| EPS Basic | 64.79% | 59.46% | 43.84% | 21.28% | 10.29% |
| Normalized Basic EPS | 61.05% | 68.57% | 53.09% | 30.83% | 9.65% |
| EPS Diluted | 64.79% | 59.46% | 43.84% | 21.28% | 10.29% |
| Normalized Diluted EPS | 61.05% | 68.57% | 53.09% | 30.83% | 9.65% |
| Average Basic Shares Outstanding | 146.21% | 368.26% | 347.71% | 245.82% | 137.95% |
| Average Diluted Shares Outstanding | 146.21% | 368.26% | 347.71% | 245.82% | 137.95% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
